Evaluating the Effect of Cabergoline on Glycaemic Control of Patients with Type 2 Diabetes Mellitus: A Randomised Controlled Trial

Evaluating the Effect of Cabergoline on Glycaemic Control of Patients with Type 2 Diabetes Mellitus: A Randomised Controlled Trial


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: اکبر علی عسگرزاده , ساناز کریمی اول , جلیل هوشیار قراملکی , مرتضی قوجازاده , علیرضا هادی

کلمات کلیدی: Fasting blood glucose, HbA1C, Long acting dopamine agonist

نشریه: 19694 , 2 , 14 , 2020

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله اکبر علی عسگرزاده
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه مرکز تحقیقات غدد درون ریز
کد مقاله 74695
عنوان فارسی مقاله Evaluating the Effect of Cabergoline on Glycaemic Control of Patients with Type 2 Diabetes Mellitus: A Randomised Controlled Trial
عنوان لاتین مقاله Evaluating the Effect of Cabergoline on Glycaemic Control of Patients with Type 2 Diabetes Mellitus: A Randomised Controlled Trial
ناشر 5
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ بلی
عنوان نشریه (خارج از لیست فوق)
نوع مقاله Original Article
نحوه ایندکس شدن مقاله ایندکس شده سطح یک – ISI - Web of Science
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

Introduction: Although bromocriptine has been approved as an antidiabetic agent, few studies have reported the benefcial effects of other anti-hyperglycemic long acting dopamine agonist agents. In this regard, Cabergoline has fewer side-effects than that of Bromocriptine which can be administered as one or two days per week with higher compliance rates in patients. Aim: To determine the effect of Cabergoline on glycaemic control in patients with Type 2 Diabetes Mellitus (DM). Materials and Methods: In this double-blind clinical trial, initial laboratory parameters including Fasting Plasma Glucose (FBS), 2 Hours Postprandial Plasma Glucose (2HPPG), HbA1c, Total Cholesterol (T-Chol), Triglycerides (TG), and High Density Lipoproteins (HDL) were assessed. The subjects were randomly assigned into two case and control groups. The intervention group received 0.25 mg Cabergoline tablets weekly for the frst 2 weeks and 0.5 mg per week for the next 12 weeks. Control group also received placebo tablets. All clinical and laboratory assessments were repeated 3 months after initial visit. Paired t-test, independent t-test and chi-square were used for the comparison of quantitative and qualitative variables, respectively. Covariance analysis was also used to adjust for confounding variables. p<0.05 was considered as statistically signifcant. Results: HbA1c (p=0.01) and TG (0.04) levels were signifcantly decreased after intervention in the case group compared to the controls. Conclusion: Cabergoline, over a 3 months period, exhibits benefcial effects on HbA1C and TG levels and may possibly be useful as a long-term anti-diabetic drug in patients with type 2 DM.

نویسندگان
hide/show

نویسنده نفر چندم مقاله
اکبر علی عسگرزادهاول
ساناز کریمی اولدوم
جلیل هوشیار قراملکیسوم
مرتضی قوجازادهچهارم
علیرضا هادیپنجم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
Evaluating_the_Effect_of_Cabergoline_on_Glycaemic_.pdf1399/10/06257333دانلود